The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone
Abstract
BACKGROUND: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults. A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after standard therapy. We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease. METHODS: Patients 30 years old or younger with Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone were eligible. The patients were randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating with courses of ifosfamide and etoposide. RESULTS: A total of 518 patients met the eligibility requirements. Of 120 patients with metastatic disease, 62 were randomly assigned to the standard-therapy group and 58 to the experimental-therapy group. There was no significant difference in five-year event-free survival between the treatment groups (P=0.81). Among the 398 patients with nonmetastatic disease, the mean (+/-SE) five-year event-free survival among the 198 patients in the experimental-therapy group was 69+/-3 percent, as compared with 54+/-4 percent among the 200 patients in the standard-therapy group (P=0.005). Overall survival was also significantly better among patients in the experimental-therapy group (72+/-3.4 percent vs. 61+/-3.6 percent in the standard-therapy group, P=0.01). CONCLUSIONS: The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Sorensen, P. H. B., Lessnick, S. L., Lopez-Terrada, D., Liu, X. F., Triche, T. J., & Denny, C. T. (1994) · Nature Genetics · doi:10.1038/ng0294-146 · Cited by 747
Nesbit, M. E., Gehan, E. A., Burgert, E. O., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., & Kissane, J. M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.10.1664 · Cited by 570
Self-citationTurc-Carel, C., Aurias, A., Mugneret, F., Lizard, S., Sidaner, I., Volk, C., Thiery, J. P., Olschwang, S., Philip, I., Berger, M. P., et al. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90285-3 · Cited by 466
Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86
Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1818 · Cited by 445
Jürgens, H., Exner, U., Gadner, H., Harms, D., Michaelis, J., Sauer, R., Treuner, J., Voûte, T., Winkelmann, W., Winkler, K., et al. (1988) · Cancer · doi:10.1002/1097-0142(19880101)61:1<23::aid-cncr2820610106>3.0.co;2-m · Cited by 417
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Self-citationCytogenetic characterization of selected small round cell tumors of childhood
Whang-Peng, J., Triche, T. J., Knutsen, T., Miser, J., Kao-Shan, S., Tsai, S., & Israel, M. A. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90001-4 · Cited by 306
Self-citationAntman, K. H., Ryan, L., Elias, A., Sherman, D., & Grier, H. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.1.126 · Cited by 241
Self-citationCraft, A. W., Cotterill, S. J., Malcolm, A., Spooner, D. A., Grimer, R. J., Souhami, R. L., Imeson, J., & Lewis, I. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3628 · Cited by 226
Kushner, B. H., Meyers, P. A., Gerald, W. L., Healey, J. H., La Quaglia, M. P., Boland, P., Wollner, N., Casper, E. S., Aledo, A., & Heller, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2796 · Cited by 163
Self-citationKung, F., Pratt, C. B., Vega, R. A., Jaffe, N., Strother, D. R., Schwenn, M. R., Nitschke, R., Homans, A. C., Holbrook, C. T., Golembe, B., et al. (1993) · Cancer · doi:10.1002/1097-0142(19930301)71:5<1898::aid-cncr2820710529>3.0.co;2-q · Cited by 113
Oberlin, O., Habrand, J., Zucker, J. M., Brunat-Mentigny, M., Terrier-Lacombe, M.-J., Dubousset, J., Gentet, J. C., Schmitt, C., Ponvert, D., & Carrié, C. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1407 · Cited by 98
Bacci, G., Picci, P., Ferrari, S., Mercuri, M., del Prever, A. B., Rosito, P., Barbieri, E., Tienghi, A., & Forni, C. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980315)82:6<1174::aid-cncr24>3.0.co;2-2 · Cited by 86
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people
MAGRATH, I. T., Sandlund, J. T., Raynor, A., Rosenberg, S. A., Arasi, V., & Miser, J. S. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00647446 · Cited by 73
Self-citation
Cited by
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
“The improved outcome noted in the early 1990s and thereafter may reflect benefits of ifosfamide and etoposide, which in a randomized study improved outcome in patients with localized Ewing sarcoma family of tumors.(32) For both osteosarcoma and Ewing sarcoma, patients presenting with metastatic disease continue to hav…”
BackgroundWomer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., Marcus, K., Sailer, S., Healey, J. H., Dormans, J. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5703 · Cited by 757
Self-citationEwing Sarcoma: Current Management and Future Approaches Through Collaboration
Gaspar, N., Hawkins, D. S., Dirksen, U., Lewis, I. J., Ferrari, S., Le Deley, M.-C., Kovar, H., Grimer, R., Whelan, J., Claude, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5256 · Cited by 722
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Balamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Metadata
- Authors
- Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., Donaldson, S. S., Moore, S., Rausen, A. R., Vietti, T. J., & Miser, J. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-02-20
- Volume
- 348
- Issue
- 8
- Pages
- 694-701
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2072315137
- Cited by
- 1,328
- References
- 16
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.